Jazz Pharmaceuticals Director Patrick Kennedy Files Form 144 for $858K Proposed Sale

Overview

On August 31, 2026, Patrick Kennedy, a Director of Jazz Pharmaceuticals plc ($JAZZ), submitted a Form 144 notice indicating an intent to sell 3,507 ordinary/common shares with an estimated aggregate market value of $857,602.00 (~$244.54 per share).

Transaction Details

• Securities to be Sold: 3,507 Common Shares
• Estimated Value: $857,602.00
• Acquisition History: The 3,507 shares were acquired on August 28, 2026, via restricted stock vesting as part of equity compensation.
• Executing Broker: E*TRADE Financial Corporation
• Market Context: The proposed sale represents a negligible fraction of the company's 64,914,577 outstanding shares (<0.01%).

Significance

The trading significance is rated Low. The proposed sale represents a standard monetization of recently vested equity compensation (RSUs) by a director and does not indicate unusual insider sentiment or material changes in shareholding.